Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
1.
J Clin Psychiatry ; 84(3)2023 03 15.
Article in English | MEDLINE | ID: mdl-36920279

ABSTRACT

Objective: Clozapine is the most efficacious antipsychotic medication, but it is underutilized and its mechanism of action is still poorly understood. One aspect of its unique efficacy that requires further study is its effect on suicidality. A randomized controlled trial, the InterSePT study, yielded evidence that clozapine reduces suicidality more than olanzapine, after which it became the only medication indicated for recurrent suicidal behavior in schizophrenia and schizoaffective disorder. We present here the first study of population mortality data to investigate the effect of clozapine on suicide.Methods: We reviewed statewide autopsy records of Maryland's Office of the Chief Medical Examiner, which performs uniquely comprehensive death investigations that include full toxicologic panels with postmortem blood levels of antipsychotics. Our study compared clozapine- and olanzapine-positive decedents across demographic, clinical, and manner-of-death outcomes using contingency table analysis and logistic regression.Results: Of 53,144 decedents from 2003 to 2021, 621 had clozapine or olanzapine detected on autopsy, with the two groups showing no demographic differences. Decedents with clozapine were significantly less likely to have died by suicide than by accident compared to those with olanzapine (odds ratio = 0.47; 95% CI, 0.26-0.84; P = .011).Conclusions: Our study thus adds more naturalistic evidence to the growing literature on the beneficial effect of clozapine on suicidality. Our findings also highlight the utility of statewide autopsy records, an untapped resource for investigating the potential protective effect of psychiatric medications on suicide at a population level.


Subject(s)
Antipsychotic Agents , Clozapine , Suicide , Humans , Clozapine/therapeutic use , Olanzapine , Maryland/epidemiology , Autopsy , Benzodiazepines/adverse effects , Antipsychotic Agents/adverse effects , Suicide/psychology , Randomized Controlled Trials as Topic
2.
Mol Psychiatry ; 28(5): 2018-2029, 2023 May.
Article in English | MEDLINE | ID: mdl-36732587

ABSTRACT

Seven Tesla magnetic resonance spectroscopy (7T MRS) offers a precise measurement of metabolic levels in the human brain via a non-invasive approach. Studying longitudinal changes in brain metabolites could help evaluate the characteristics of disease over time. This approach may also shed light on how the age of study participants and duration of illness may influence these metabolites. This study used 7T MRS to investigate longitudinal patterns of brain metabolites in young adulthood in both healthy controls and patients. A four-year longitudinal cohort with 38 patients with first episode psychosis (onset within 2 years) and 48 healthy controls was used to examine 10 brain metabolites in 5 brain regions associated with the pathophysiology of psychosis in a comprehensive manner. Both patients and controls were found to have significant longitudinal reductions in glutamate in the anterior cingulate cortex (ACC). Only patients were found to have a significant decrease over time in γ-aminobutyric acid, N-acetyl aspartate, myo-inositol, total choline, and total creatine in the ACC. Together we highlight the ACC with dynamic changes in several metabolites in early-stage psychosis, in contrast to the other 4 brain regions that also are known to play roles in psychosis. Meanwhile, glutathione was uniquely found to have a near zero annual percentage change in both patients and controls in all 5 brain regions during a four-year follow-up in young adulthood. Given that a reduction of the glutathione in the ACC has been reported as a feature of treatment-refractory psychosis, this observation further supports the potential of glutathione as a biomarker for this subset of patients with psychosis.


Subject(s)
Glutamine , Psychotic Disorders , Humans , Young Adult , Adult , Glutamine/metabolism , Psychotic Disorders/metabolism , Brain/metabolism , Glutamic Acid/metabolism , Gyrus Cinguli/metabolism , Aspartic Acid/metabolism , Glutathione/metabolism
3.
World J Biol Psychiatry ; 24(2): 178-186, 2023 02.
Article in English | MEDLINE | ID: mdl-35678361

ABSTRACT

OBJECTIVES: Olfactory dysfunction is reproducibly reported in psychotic disorders, particularly in association with negative symptoms. The superior frontal gyrus (SFG) has been frequently studied in patients with psychotic disorders, in particular with their associations with negative symptoms. The relationship between olfactory functions and brain structure has been studied in healthy controls (HCs). Nevertheless, the studies with patients with psychotic disorders are limited. Here we report the olfactory-brain relationship in a first episode psychosis (FEP) cohort through both hypothesis-driven (centred on the SFG) and data-driven approaches. METHODS: Using data from 88 HCs and 76 FEP patients, we evaluated the correlation between olfactory functions and structural/resting-state functional magnetic resonance imaging (MRI) data. RESULTS: We found a significant correlation between the left SFG volume and odour discrimination in FEP patients, but not in HCs. We also observed a significant correlation between rs-fMRI connectivity involving the left SFG and odour discrimination in FEP patients, but not in HCs. The data-driven approach didn't observe any significant correlations, possibly due to insufficient statistical power. CONCLUSION: The left SFG may be a promising brain region in the context of olfactory dysfunction and negative symptoms in FEP.


Subject(s)
Olfaction Disorders , Psychotic Disorders , Schizophrenia , Humans , Magnetic Resonance Imaging , Psychotic Disorders/complications , Brain/pathology , Olfaction Disorders/complications
4.
Transl Psychiatry ; 12(1): 99, 2022 03 10.
Article in English | MEDLINE | ID: mdl-35273151

ABSTRACT

Under the hypothesis that olfactory neural epithelium gene expression profiles may be useful to look for disease-relevant neuronal signatures, we examined microarray gene expression in olfactory neuronal cells and underscored Notch-JAG pathway molecules in association with schizophrenia (SZ). The microarray profiling study underscored JAG1 as the most promising candidate. Combined with further validation with real-time PCR, downregulation of NOTCH1 was statistically significant. Accordingly, we reverse-translated the significant finding from a surrogate tissue for neurons, and studied the behavioral profile of Notch1+/- mice. We found a specific impairment in social novelty recognition, whereas other behaviors, such as sociability, novel object recognition and olfaction of social odors, were normal. This social novelty recognition deficit was male-specific and was rescued by rapamycin treatment. Based on the results from the animal model, we next tested whether patients with psychosis might have male-specific alterations in social cognition in association with the expression of NOTCH1 or JAG1. In our first episode psychosis cohort, we observed a specific correlation between the expression of JAG1 and a face processing measure only in male patients. The expression of JAG1 was not correlated with any other cognitive and symptomatic scales in all subjects. Together, although we acknowledge the pioneering and exploratory nature, the present work that combines both human and animal studies in a reciprocal manner suggests a novel role for the Notch-JAG pathway in a behavioral dimension(s) related to social cognition in psychotic disorders in a male-specific manner.


Subject(s)
Psychotic Disorders , Animals , Down-Regulation , Female , Humans , Male , Mice , Olfactory Mucosa
5.
Mol Psychiatry ; 27(2): 1184-1191, 2022 02.
Article in English | MEDLINE | ID: mdl-34642460

ABSTRACT

Treatment resistant (TR) psychosis is considered to be a significant cause of disability and functional impairment. Numerous efforts have been made to identify the clinical predictors of TR. However, the exploration of molecular and biological markers is still at an early stage. To understand the TR condition and identify potential molecular and biological markers, we analyzed demographic information, clinical data, structural brain imaging data, and molecular brain imaging data in 7 Tesla magnetic resonance spectroscopy from a first episode psychosis cohort that includes 136 patients. Age, gender, race, smoking status, duration of illness, and antipsychotic dosages were controlled in the analyses. We found that TR patients had a younger age at onset, more hospitalizations, more severe negative symptoms, a reduction in the volumes of the hippocampus (HP) and superior frontal gyrus (SFG), and a reduction in glutathione (GSH) levels in the anterior cingulate cortex (ACC), when compared to non-TR patients. The combination of multiple markers provided a better classification between TR and non-TR patients compared to any individual marker. Our study shows that ACC-GSH, HP and SFG volumes, and age at onset, could potentially be biomarkers for TR diagnosis, while hospitalization and negative symptoms could be used to evaluate the progression of the disease. Multimodal cohorts are essential in obtaining a comprehensive understanding of brain disorders.


Subject(s)
Antipsychotic Agents , Psychotic Disorders , Schizophrenia , Antipsychotic Agents/therapeutic use , Biomarkers , Humans , Magnetic Resonance Imaging , Psychotic Disorders/diagnosis , Psychotic Disorders/drug therapy
6.
BMC Psychiatry ; 21(1): 76, 2021 02 06.
Article in English | MEDLINE | ID: mdl-33549083

ABSTRACT

BACKGROUND: Neutropenia, a decrease in total number of neutrophils below 1500/mm3 and particularly severe neutropenia, defined as neutrophils less than 500/mm3, is a potential adverse effect of antipsychotic medications that can lead to increased risk of infections and death. However, much of the attention on the potential adverse effect is centered exclusively on clozapine, which remains the only antipsychotic medication in the United States requiring standardized monitoring of blood work. We demonstrate here that paliperidone can also cause neutropenia and therefore clinicians should be aware of this possibility especially during initiation of treatment. CASE PRESENTATION: The following report presents the case of a 23-year-old African American male with first episode psychosis who developed neutropenia after initiation of paliperidone. Neutropenia resolved after discontinuation of paliperidone and initiation of an alternative antipsychotic, haloperidol. CONCLUSIONS: This case report demonstrates an example of paliperidone induced neutropenia which resolved with a switch to haloperidol. We conclude that when initiating paliperidone, clinicians should be more aware of the risk of neutropenia. Moreover, neutropenia may be a more common and overlooked issue in patients on antipsychotic medications other than clozapine and increased awareness of comparative risk across antipsychotics could help direct treatment.


Subject(s)
Antipsychotic Agents , Clozapine , Neutropenia , Psychotic Disorders , Schizophrenia , Adult , Antipsychotic Agents/adverse effects , Clozapine/therapeutic use , Humans , Male , Neutropenia/chemically induced , Neutropenia/drug therapy , Paliperidone Palmitate/adverse effects , Psychotic Disorders/drug therapy , Schizophrenia/drug therapy , United States , Young Adult
7.
J Clin Psychopharmacol ; 41(2): 180-185, 2021.
Article in English | MEDLINE | ID: mdl-33587399

ABSTRACT

BACKGROUND: Clozapine is the only medication with Food and Drug Administration approval for treatment-resistant schizophrenia. However, it is underutilized in the United States because of several life-threatening adverse effects, including clozapine-associated myocarditis (CAM), and a limited understanding of how to manage these complications. To date, recommendations for rechallenging patients with CAM that incorporate the cardiac literature or cardioprotective medications have not been developed. FINDINGS: In this article, we outline a protocol developed with cardiologists and guided by the cardiac literature that provides direction on how to monitor for the initial development of CAM and how to rechallenge patients with CAM. Furthermore, we present 2 successful cases of clozapine rechallenge that were managed using this protocol. CONCLUSIONS: In both cases, the patients showed marked improvement in their psychiatric symptoms and functioning, demonstrating the importance of considering rechallenge in patients after CAM.


Subject(s)
Antipsychotic Agents/adverse effects , Clozapine/adverse effects , Myocarditis/chemically induced , Adult , Antipsychotic Agents/administration & dosage , Cardiotonic Agents/administration & dosage , Clozapine/administration & dosage , Humans , Male , Myocarditis/diagnosis , Myocarditis/drug therapy , Schizophrenia/drug therapy
9.
J Cell Physiol ; 235(10): 7309-7320, 2020 10.
Article in English | MEDLINE | ID: mdl-32180220

ABSTRACT

Parkinson's disease (PD) is one of the most common movement disorders with loss of dopaminergic neurons and the presence of Lewy bodies in certain brain areas. However, it is not clear how Lewy body (inclusion with protein aggregation) formation occurs. Mutations in leucine-rich repeat kinase 2 (LRRK2) can cause a genetic form of PD and contribute to sporadic PD with the typical Lewy body pathology. Here, we used our recently identified LRRK2 GTP-binding inhibitors as pharmacological probes to study the LRRK2-linked ubiquitination and protein aggregation. Pharmacological inhibition of GTP-binding by GTP-binding inhibitors (68 and Fx2149) increased LRRK2-linked ubiquitination predominantly via K27 linkage. Compound 68- or Fx2149 increased G2019S-LRRK2-linked ubiquitinated aggregates, which occurred through the atypical linkage types K27 and K63. Coexpression of K27R and K63R, which prevented ubiquitination via K27 and K63 linkages, reversed the effects of 68 and Fx2149. Moreover, 68 and Fx2149 also promoted G2019S-LRRK2-linked aggresome (Lewy body-like inclusion) formation via K27 and K63 linkages. These findings demonstrate that LRRK2 GTP-binding activity is critical in LRRK2-linked ubiquitination and aggregation formation. These studies provide novel insight into the LRRK2-linked Lewy body-like inclusion formation underlying PD pathogenesis.


Subject(s)
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/metabolism , Lewy Bodies/metabolism , Animals , Brain/drug effects , Brain/metabolism , Brain/pathology , Guanosine Triphosphate/metabolism , HEK293 Cells , Humans , Inclusion Bodies/metabolism , Inclusion Bodies/pathology , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/chemistry , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/genetics , Lewy Bodies/pathology , Mice , Mice, Inbred C57BL , Mutant Proteins/chemistry , Mutant Proteins/genetics , Mutant Proteins/metabolism , Mutation , Parkinson Disease/genetics , Parkinson Disease/metabolism , Parkinson Disease/pathology , Protein Aggregation, Pathological/genetics , Protein Aggregation, Pathological/metabolism , Protein Aggregation, Pathological/pathology , Protein Binding , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Ubiquitination
10.
Hum Mol Genet ; 29(4): 580-590, 2020 03 13.
Article in English | MEDLINE | ID: mdl-31813996

ABSTRACT

Parkinson's disease (PD) is a common neurodegenerative disease with a heterogeneous etiology that involves genetic and environmental factors or exogenous. Current LRRK2 PD animal models only partly reproduce the characteristics of the disease with very subtle dopaminergic neuron degeneration. We developed a new model of PD that combines a sub-toxic MPTP insult to the G2019S-LRRK2 mutation. Our newly generated mice, overexpressing mutant G2019S-LRRK2 protein in the brain, displayed a mild, age-dependent progressive motor impairment, but no reduction of lifespan. Cortical neurons from G2019S-LRRK2 mice showed an increased vulnerability to stress insults, compared with neurons overexpressing wild-type WT-LRRK2, or non-transgenic (nTg) neurons. The exposure of LRRK2 transgenic mice to a sub-toxic dose of MPTP resulted in severe motor impairment, selective loss of dopamine neurons and increased astrocyte activation, whereas nTg mice with MPTP exposure showed no deficits. Interestingly, mice overexpressing WT-LRRK2 showed a significant impairment that was milder than for the mutant G2019S-LRRK2 mice. L-DOPA treatments could partially improve the movement impairments but did not protect the dopamine neuron loss. In contrast, treatments with an LRRK2 kinase inhibitor significantly reduced the dopaminergic neuron degeneration in this interaction model. Our studies provide a novel LRRK2 gene-MPTP interaction PD mouse model, and a useful tool for future studies of PD pathogenesis and therapeutic intervention.


Subject(s)
Dopamine/metabolism , Dopaminergic Neurons/pathology , Leucine-Rich Repeat Serine-Threonine Protein Kinase-2/genetics , Motor Disorders/pathology , Mutation , Parkinsonian Disorders/pathology , Animals , Dopaminergic Neurons/metabolism , Female , Male , Mice , Mice, Transgenic , Motor Disorders/etiology , Motor Disorders/metabolism , Parkinsonian Disorders/etiology , Parkinsonian Disorders/metabolism
11.
Am J Psychiatry ; 176(9): 730-743, 2019 09 01.
Article in English | MEDLINE | ID: mdl-31055969

ABSTRACT

OBJECTIVE: The mechanisms leading to schizophrenia are likely to be diverse. However, there may be common pathophysiological pathways for subtypes of the disease. The authors tested the hypothesis that increased protein insolubility and ubiquitination underlie the pathophysiology for a subtype of schizophrenia. METHODS: Prefrontal cortex and superior temporal gyrus from postmortem brains of individuals with and without schizophrenia were subjected to cold sarkosyl fractionation, separating proteins into soluble and insoluble fractions. Protein insolubility and ubiquitin levels were quantified for each insoluble fraction, with normalization to total homogenate protein. Mass spectrometry analysis was then performed to identify the protein contents of the insoluble fractions. The potential biological relevance of the detected proteins was assessed using Gene Ontology enrichment analysis and Ingenuity Pathway Analysis. RESULTS: A subset of the schizophrenia brains showed an increase in protein insolubility and ubiquitination in the insoluble fraction. Mass spectrometry of the insoluble fraction revealed that brains with increased insolubility and ubiquitination exhibited a similar peptide expression by principal component analysis. The proteins that were significantly altered in the insoluble fraction were enriched for pathways relating to axon target recognition as well as nervous system development and function. CONCLUSIONS: This study suggests a pathological process related to protein insolubility for a subset of patients with schizophrenia. Determining the molecular mechanism of this subtype of schizophrenia could lead to a better understanding of the pathways underlying the clinical phenotype in some patients with major mental illness as well as to improved nosology and identification of novel therapeutic targets.


Subject(s)
Brain/metabolism , Nerve Tissue Proteins/metabolism , Schizophrenia/metabolism , Animals , Antipsychotic Agents/pharmacology , Blotting, Western , Brain/drug effects , Brain/pathology , Case-Control Studies , Female , Gas Chromatography-Mass Spectrometry , Haloperidol/pharmacology , Humans , Male , Mass Spectrometry , Middle Aged , Prefrontal Cortex/metabolism , Prefrontal Cortex/pathology , Rats , Rats, Sprague-Dawley , Risperidone/pharmacology , Schizophrenia/etiology , Schizophrenia/physiopathology , Solubility , Temporal Lobe/metabolism , Temporal Lobe/pathology , Ubiquitination
13.
Neuropsychology ; 33(2): 203-211, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30475048

ABSTRACT

OBJECTIVE: First-episode schizophrenia and schizoaffective patients (SZ+) show olfactory impairments, but how these relate to cognitive dysfunction remains unclear. We examined the relationship between cognitive and olfactory dysfunction in SZ+ and the clinical utility of these measures in the assessment of SZ+ patients. METHOD: First-episode SZ+ patients (n = 63) and controls (n = 63) were administered tests of odor identification and discrimination in addition to measures of manual dexterity, processing speed, attention and working memory, executive functioning, ideational fluency, and memory. We analyzed the relationships between olfactory and cognitive variables and conducted stepwise multiple regressions to identify which cognitive indices best predicted olfactory performance within the SZ+ group. Linear discriminant analysis was used to identify which measures best distinguished cases from controls. RESULTS: Among patients, odor discrimination correlated with perseverative errors and odor identification correlated with bilateral manual dexterity. Odor discrimination performance was best predicted by perseverative errors and letter fluency, whereas odor identification ability was best predicted by manual dexterity. Stepwise linear discriminant analysis revealed that manual dexterity, letter-guided word fluency, and odor discrimination best distinguished SZ+ from healthy adults. CONCLUSIONS: These findings indicate that manual dexterity, letter-guided word fluency, and odor discrimination may provide incremental information that strengthens a diagnosis of SZ+. Although odor discrimination tasks have received limited attention in schizophrenia studies, the extant data along with the present results indicate that odor discrimination tasks may have utility over odor identification measures as a neurodevelopmental risk marker. Additional studies examining odor discrimination as a predictor of SZ spectrum illness are warranted. (PsycINFO Database Record (c) 2019 APA, all rights reserved).


Subject(s)
Executive Function/physiology , Olfaction Disorders/diagnosis , Schizophrenia/diagnosis , Smell/physiology , Adolescent , Adult , Attention/physiology , Female , Humans , Male , Neuropsychological Tests , Odorants , Olfaction Disorders/complications , Olfaction Disorders/physiopathology , Schizophrenia/complications , Schizophrenia/physiopathology , Young Adult
14.
Neurobiol Dis ; 131: 104257, 2019 11.
Article in English | MEDLINE | ID: mdl-30170114

ABSTRACT

Treatment resistant schizophrenia (TRS) refers to the significant proportion of schizophrenia patients who continue to have symptoms and poor outcomes despite treatment. While many definitions of TRS include failure of two different antipsychotics as a minimum criterion, the wide variability in inclusion criteria has challenged the consistency and reproducibility of results from studies of TRS. We begin by reviewing the clinical, neuroimaging, and neurobiological characteristics of TRS. We further review the current treatment strategies available, addressing clozapine, the first-line pharmacological agent for TRS, as well as pharmacological and non-pharmacological augmentation of clozapine including medication combinations, electroconvulsive therapy, repetitive transcranial magnetic stimulation, deep brain stimulation, and psychotherapies. We conclude by highlighting the most recent consensus for defining TRS proposed by the Treatment Response and Resistance in Psychosis Working Group, and provide our overview of future perspectives and directions that could help advance the field of TRS research, including the concept of TRS as a potential subtype of schizophrenia.


Subject(s)
Schizophrenia/physiopathology , Schizophrenia/therapy , Drug Resistance , Humans
15.
Sci Adv ; 4(8): eaar6637, 2018 08.
Article in English | MEDLINE | ID: mdl-30116778

ABSTRACT

Individuals with chromosome 22q11.2 deletions are at increased risk of developing psychiatric conditions, most notably, schizophrenia (SZ). Recently, clinical studies have also implicated these recurrent 22q11.2 deletions with the risk of early-onset Parkinson's disease (PD). Thus far, the multiple mouse models generated for 22q11.2 deletions have been studied primarily in the context of congenital cardiac, neurodevelopmental, and psychotic disorders. One of these is the Df1/+ model, in which SZ-associated and developmental abnormalities have been reported. We present the first evidence that the mouse model for the 22q11.2 deletion exhibits motor coordination deficits and molecular signatures (that is, elevated α-synuclein expression) relevant to PD. Reducing the α-synuclein gene dosage in Df1/+ mice ameliorated the motor deficits. Thus, this model of the 22q11.2 deletion shows signatures of both SZ and PD at the molecular and behavioral levels. In addition, both SZ-associated and PD-relevant deficits in the model were ameliorated by treatment with a rapamycin analog, CCI-779. We now posit the utility of 22q11.2 deletion mouse models in investigating the mechanisms of SZ- and PD-associated manifestations that could shed light on possible common pathways of these neuropsychiatric disorders.


Subject(s)
Behavior, Animal , Chromosomes, Human, Pair 22/genetics , Disease Models, Animal , Parkinson Disease/etiology , Schizophrenia/etiology , Sequence Deletion , alpha-Synuclein/genetics , Animals , DiGeorge Syndrome , Humans , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Parkinson Disease/pathology , Parkinson Disease/psychology , Schizophrenia/pathology
16.
Front Psychiatry ; 8: 150, 2017.
Article in English | MEDLINE | ID: mdl-28861008

ABSTRACT

Atypical antipsychotic medications, such as risperidone, aripiprazole, and olanzapine, have utility in treating motor tics, particularly in Tourette syndrome. In rare cases, atypical antipsychotic medications have been associated with adult-onset motor tics. Such adverse drug reactions have been documented in response to quetiapine, aripiprazole, and amisulpride. Here, we report, to our knowledge, the first case of adult-onset motor tics related to olanzapine administration.

17.
Neurotherapeutics ; 14(3): 750-761, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28653280

ABSTRACT

Schizophrenia is a devastating illness that affects up to 1% of the population; it is characterized by a combination of positive symptoms, negative symptoms, and cognitive impairment. Currently, treatment consists of one class of medications known as antipsychotics, which include typical (first-generation) and atypical (second-generation) agents. Unfortunately, antipsychotic medications have limited efficacy, with up to a third of patients lacking a full response. Clozapine, the first atypical antipsychotic developed, is the only medication shown to be superior to all other antipsychotics. However, owing to several life-threatening side effects and required enrollment in a registry with routine blood monitoring, clozapine is greatly underutilized in the US. Developing a medication as efficacious as clozapine with limited side effects would likely become the first-line therapy for schizophrenia and related disorders. In this review, we discuss the history of clozapine, landmark studies, and its clinical advantages and disadvantages. We further discuss the hypotheses for clozapine's superior efficacy based on neuroreceptor binding, and the limitations of a receptor-based approach to antipsychotic development. We highlight some of the advances from pharmacogenetic studies on clozapine and then focus on studies of clozapine using unbiased approaches such as pharmacogenomics and gene expression profiling. Finally, we examine how these approaches could provide insights into clozapine's mechanism of action and side-effect profile, and lead to novel and improved therapeutics.


Subject(s)
Antipsychotic Agents/pharmacology , Clozapine/pharmacology , Schizophrenia/drug therapy , Animals , Humans
18.
Psychiatr Serv ; 68(8): 847-850, 2017 Aug 01.
Article in English | MEDLINE | ID: mdl-28366115

ABSTRACT

OBJECTIVE: This study examined whether outpatients with a psychotic disorder who are at risk of hospitalization can be identified by using data from electronic medical records (EMRs). METHODS: Data from EMRs of outpatients enrolled in two clinics for treatment of psychotic disorders were abstracted. Monthly data were collected for 75 patients over two years. The study examined the association of medication nonadherence, substance use, participation in psychiatric rehabilitation, and long-acting injectable antipsychotic use in any given month with the risk of hospitalization in the subsequent month by using generalized estimating equations. RESULTS: The only variable found to increase the relative risk of future hospitalization was recorded medication nonadherence (adjusted relative risk=7.19, p<.001). CONCLUSIONS: Results suggest that recording medication nonadherence in EMRs is feasible and that these data may be used to identify patients at high risk of future hospitalization, who may require more intensive intervention.


Subject(s)
Antipsychotic Agents/therapeutic use , Electronic Health Records/statistics & numerical data , Hospitalization/statistics & numerical data , Medication Adherence/statistics & numerical data , Psychotic Disorders/therapy , Adolescent , Adult , Female , Humans , Male , Middle Aged , Psychotic Disorders/drug therapy , Risk , Young Adult
19.
Schizophr Res ; 185: 58-66, 2017 07.
Article in English | MEDLINE | ID: mdl-28038920

ABSTRACT

Clozapine is the only medication indicated for treating refractory schizophrenia, due to its superior efficacy among all antipsychotic agents, but its mechanism of action is poorly understood. To date, no studies of human postmortem brain have characterized the gene expression response to clozapine. Therefore, we addressed this question by analyzing expression data extracted from published microarray studies involving brains of patients on antipsychotic therapy. We first performed a systematic review and identified four microarray studies of postmortem brains from antipsychotic-treated patients, then extracted the expression data. We then performed generalized linear model analysis on each study separately, and identified the genes differentially expressed in response to clozapine compared to other atypical antipsychotic medications, as well as their associated canonical pathways. We also found a number of genes common to all four studies that we analyzed: GCLM, ZNF652, and GYPC. In addition, pathway analysis highlighted the following processes in all four studies: clathrin-mediated endocytosis, SAPK/JNK signaling, 3-phosphoinositide synthesis, and paxillin signaling. Our analysis yielded the first comprehensive compendium of genes and pathways differentially expressed upon clozapine treatment in the human brain, which may provide insight into the mechanism and unique efficacy of clozapine, as well as the pathophysiology of schizophrenia.


Subject(s)
Antipsychotic Agents/therapeutic use , Brain/drug effects , Clozapine/therapeutic use , Gene Expression/drug effects , Schizophrenia , Signal Transduction/drug effects , Autopsy , Brain/physiopathology , Databases, Bibliographic/statistics & numerical data , Female , Humans , Male , Schizophrenia/drug therapy , Schizophrenia/pathology , Schizophrenia/physiopathology , Signal Transduction/genetics
20.
Mol Neuropsychiatry ; 2(3): 133-144, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27867938

ABSTRACT

Schizophrenia and other major mental illnesses result from a complex interplay of genetic and environmental factors. We previously identified a mutation in NPAS3 that results in a valine to isoleucine (V304I) amino acid substitution segregating with schizophrenia in a small family. The amino acid change occurs in a potentially critical region for protein function. Furthermore, the same amino acid substitution in proteins related to familial Alzheimer's disease and transthyretin amyloidosis has been associated with protein aggregation. In this study, we demonstrate that NPAS3 is prone to aggregation, and that the V304I mutation in NPAS3 increases this propensity in both bacterial and mammalian expression systems. We also show that NPAS3-V304I reduces soluble endogenous NPAS3, and increases insoluble endogenous NPAS3 and leads to alteration of transcriptional activity. These results suggest that protein aggregation, potentially leading to cell dysfunction via a loss of protein function through sequestration, may contribute to the pathogenesis of schizophrenia and other forms of mental illness. Further exploration of the mechanisms leading to abnormal protein quality control could lead to new therapeutic targets.

SELECTION OF CITATIONS
SEARCH DETAIL
...